Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

Масштабируемое полное экзомное секвенирование внеклеточной ДНК выявляет высокую конкордантность с метастатическими опухолями
Ofir Cohen, Matthew M. Meyerson, Gad A. Getz, Karla E. Helvie, Sara M. Tolaney, Eric P. Winer, Nikhil Wagle, Todd R. Golub, Jaegil Kim, Chip Stewart, Eliezer M. Van Allen, Mara W. Rosenberg, John Christopher Love, Paz P Polak, Adrienne Gropper Waks, Huiming Ding, Cheng‐Zhong Zhang, Levi A. Garraway, Gavin Ha, Ignaty Leshchiner, Dimitri G. Livitz, Daniel Rosebrock, Jesse S. Boehm, Andrea Saltzman, Rachel M. Barry, Nelly M. Oliver, Jens G. Lohr, Molly M. Schleicher, Coyin Oh, Cory M. Johannessen, Joshua M. Francis, Mary‐Ellen Taplin, Edward P. O’Connor, Samuel S. Freeman, Daniel G. Stover, Zhenwei Zhang, Viktor A. Adalsteinsson, Sarah C. Reed, Lauren C. Harshman, Maxwell Roger Lloyd, Justin Rhoades, Gregory Gydush, Heather Anne Parsons, Rachel L. Leeson, NU Lin, Mari Nakabayashi, D. V. Loginov, Atish Dipankar Choudhury, Denisse Rotem, Sairah Mahmud, Margaret S. Merrill, Rebecca A. Santiago, Seong H. Jeong, Joseph F. Kramkowski, Laura C. Polacek, Emily Lipscomb, Lori Marini
2017-10-31

cell-free DNAcopy number alterationsichorCNAmetastatic tumorswhole-exome sequencing
Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling of tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies is uncertain. Here we report ichorCNA, software that quantifies tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations. We apply ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or breast cancers. In the earliest tested sample for each patient, 34% of patients have ≥10% tumor-derived cfDNA, sufficient for standard coverage whole-exome sequencing. Using whole-exome sequencing, we validate the concordance of clonal somatic mutations (88%), copy number alterations (80%), mutational signatures, and neoantigens between cfDNA and matched tumor biopsies from 41 patients with ≥10% cfDNA tumor content. In summary, we provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing its applicability to many patients, and demonstrate high concordance of cfDNA and metastatic tumor whole-exome sequencing.
1
Among 520 patients with metastatic prostate or breast cancer, 34% had at least 10% tumor-derived cfDNA in their earliest sample.
2
At least 10% cfDNA tumor content enabled standard-coverage whole-exome sequencing for comprehensive tumor profiling.
3
Mutational signatures and neoantigens were also concordant between cfDNA and matched tumor biopsies, supporting broad applicability of cfDNA whole-exome sequencing.
4
cfDNA and matched metastatic tumor biopsies showed concordance of 88% for clonal somatic mutations and 80% for copy-number alterations.
5
ichorCNA quantifies tumor content in cfDNA using 0.1× whole-genome sequencing without prior knowledge of tumor mutations.

cell-free DNA and matched metastatic tumor biopsies from patients with metastatic prostate or breast cancer

genome-wide concordance of whole-exome profiles, including clonal somatic mutations, copy-number alterations, mutational signatures, and neoantigens

Publication Details
Publication Date
2017-10-31
Journal
Publisher
ISSN
Cited by
1055
Access Type
Author Information
Authors
Ofir Cohen
Matthew M. Meyerson
Gad A. Getz
Karla E. Helvie
Sara M. Tolaney
Eric P. Winer
Nikhil Wagle
Todd R. Golub
Jaegil Kim
Chip Stewart
Eliezer M. Van Allen
Mara W. Rosenberg
John Christopher Love
Paz P Polak
Adrienne Gropper Waks
Huiming Ding
Cheng‐Zhong Zhang
Levi A. Garraway
Gavin Ha
Ignaty Leshchiner
Dimitri G. Livitz
Daniel Rosebrock
Jesse S. Boehm
Andrea Saltzman
Rachel M. Barry
Nelly M. Oliver
Jens G. Lohr
Molly M. Schleicher
Coyin Oh
Cory M. Johannessen
Joshua M. Francis
Mary‐Ellen Taplin
Edward P. O’Connor
Samuel S. Freeman
Daniel G. Stover
Zhenwei Zhang
Viktor A. Adalsteinsson
Sarah C. Reed
Lauren C. Harshman
Maxwell Roger Lloyd
Justin Rhoades
Gregory Gydush
Heather Anne Parsons
Rachel L. Leeson
NU Lin
Mari Nakabayashi
D. V. Loginov
Atish Dipankar Choudhury
Denisse Rotem
Sairah Mahmud
Margaret S. Merrill
Rebecca A. Santiago
Seong H. Jeong
Joseph F. Kramkowski
Laura C. Polacek
Emily Lipscomb
Lori Marini
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%